Systemic Mastocytosis

1. Disease Information

Disease Name: Systemic Mastocytosis (SM) Category: Complex clonal hematopoietic/mast cell neoplasm

Overview

Systemic mastocytosis is a rare clonal hematopoietic stem cell disease characterized by abnormal proliferation and accumulation of neoplastic mast cells in extracutaneous organs including bone marrow, skin, gastrointestinal tract, liver, and spleen (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2). The disease is caused by activating KIT mutations, predominantly KIT D816V, which induce ligand-independent KIT receptor activation and downstream signaling, leading to mast cell proliferation, survival, and activation (lee2023recentadvancesin pages 1-2, cilloni2024detectionofkit pages 1-2, toledo2023kitd816vmast pages 1-2). SM affects approximately 1 in 10,000 persons in the adult population according to Orphanet data (cilloni2024detectionofkit pages 1-2).

Key Identifiers

While specific database identifiers were not fully retrieved, systemic mastocytosis is classified in: - WHO Classification: Recognized as a distinct entity separated from myeloproliferative neoplasms since 2016, with updates in WHO 5th edition (2022) (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2) - ICC Classification: International Consensus Classification (2022) with refined criteria (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2) - ICD Classification: Categorized under mast cell disorders - Orphanet: Listed with prevalence data - Common Synonyms: Mast cell disease, clonal mast cell disorder

Data Sources

Information is derived from both disease-level aggregated resources (classification systems, expert reviews) and individual patient data compiled in registries and clinical studies (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2).

2. Etiology

Disease Causal Factors

Genetic: The primary causal factor is somatic activating mutations in the KIT gene, most frequently KIT D816V (c.2447A>T, p.Asp816Val), present in 85-90% or >90% of adult SM cases (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, toledo2023kitd816vmast pages 1-2). The KIT D816V mutation is considered the pathogenic driver, inducing constitutive activation of the KIT tyrosine kinase receptor independent of its ligand stem cell factor (SCF), affecting key cellular pathways including proliferation, differentiation, survival, and activation (toledo2023kitd816vmast pages 1-2).

Other less common KIT mutations (<5% of cases) include V560G, D815K, D816Y, D816F, D816H, D820G, and insVI815-816 (pardanani2023systemicmastocytosisin pages 1-2).

Mechanistic: KIT encodes a Type III receptor tyrosine kinase expressed on mast cells, hematopoietic stem cells, germ cells, melanocytes, and interstitial cells of Cajal. The interaction between KIT and SCF plays a critical role in mast cell development, proliferation, maturation, chemotaxis, adhesion, and survival (pardanani2023systemicmastocytosisin pages 1-2, li2023reviewandupdates pages 2-4). Gain-of-function KIT mutations cause ligand-independent receptor activation and constitutive downstream signaling (toledo2023kitd816vmast pages 1-2).

Risk Factors

Genetic Risk Factors: - Multilineage involvement of hematopoiesis by KIT D816V is associated with higher tumor burden, additional mutations, and increased transformation risk to advanced SM (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2) - Co-occurring somatic mutations in genes frequently mutated in myeloid neoplasms, including ASXL1, RUNX1, SRSF2, NRAS, TET2, DNMT3A, CBL, EZH2, JAK2, KRAS, and SF3B1, are identified particularly in advanced SM and correlate with disease progression and poor survival (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2) - Approximately 12 genes (ASXL1, CBL, DNMT3A, EZH2, JAK2, KRAS, NRAS, SF3B1, RUNX1, SRSF2, TET2) are recurrently mutated in SM - Hereditary alpha-tryptasemia (HαT), an autosomal dominant trait caused by increased TPSAB1 gene copy number encoding alpha-tryptase, shows increased prevalence (estimated 2-3×) in SM patients and may modify disease severity and symptom expression (beyens2023mastocytosisandrelated pages 1-5, li2023reviewandupdates pages 2-4)

Environmental Risk Factors: Given the clonal/genetic nature of SM, specific environmental risk factors have not been established. Age influences presentation—adults typically present between ages 20-50, while pediatric cutaneous mastocytosis occurs in ~75-80% of cases within the first two years of life (cilloni2024detectionofkit pages 1-2).

Sex: Male-to-female ratio is approximately 1:1 (cilloni2024detectionofkit pages 1-2).

Protective Factors

No specific genetic or environmental protective factors have been identified given the clonal somatic mutation etiology.

Gene-Environment Interactions

Not well established for SM given its clonal nature driven by somatic KIT mutations.

3. Phenotypes

Table: This table summarizes systemic mastocytosis classification, diagnostic criteria, KIT mutation patterns, subtype-defining features, and prognosis using recent WHO 2022 and ICC 2022/2023-aligned sources. It is useful as a compact reference for comparing non-advanced and advanced SM entities.

Clinical Manifestations by Phenotype Type

Symptoms Related to Mast Cell Mediator Release (Frequency: Common to Very Common in All SM Subtypes): - HP:0001025 Urticaria (hives) - HP:0000989 Pruritus (itching) - HP:0000963 Flushing - HP:0002014 Diarrhea - HP:0002027 Abdominal pain - HP:0002017 Nausea and vomiting - HP:0012115 Hepatomegaly - HP:0001744 Splenomegaly - HP:0000822 Hypertension (or hypotension during anaphylaxis) - HP:0001962 Palpitations/tachycardia - HP:0001279 Syncope or presyncope - HP:0012378 Fatigue - HP:0001945 Fever

Severity: Variable from mild to life-threatening Progression: Episodic or chronic Frequency: Occurs in majority of SM patients (cilloni2024detectionofkit pages 1-2, lee2023recentadvancesin pages 3-5, beyens2023mastocytosisandrelated pages 5-8)

Anaphylaxis (Frequency: Common, especially with hymenoptera venom allergy): - HP:0000969 Edema - HP:0025085 Bloody diarrhea (in severe cases) - HP:0002098 Respiratory distress - HP:0001297 Stroke (rare, severe)

Severity: Can be life-threatening Onset: Acute, triggered Frequency: Recurrent unprovoked anaphylaxis is a red flag for SM (beyens2023mastocytosisandrelated pages 1-5, beyens2023mastocytosisandrelated pages 5-8)

Cutaneous Manifestations (Frequency: Common in Indolent SM, Variable in Advanced SM): - HP:0001030 Fragile skin (in diffuse cutaneous mastocytosis) - HP:0007434 Generalized hyperpigmentation - HP:0000992 Cutaneous photosensitivity (Darier's sign—whealing upon stroking lesions) - Maculopapular cutaneous mastocytosis (urticaria pigmentosa): red-brown macules/papules

Severity: Variable Age of onset: Childhood for cutaneous mastocytosis, adult-onset often indicates ISM Frequency: Present in majority of ISM cases; less common in advanced SM (beyens2023mastocytosisandrelated pages 1-5, beyens2023mastocytosisandrelated pages 5-8)

Skeletal/Bone Manifestations (Frequency: Very Common, 30-75% of ISM patients): - HP:0000939 Osteoporosis - HP:0002659 Increased susceptibility to fractures (pathological fractures) - HP:0100774 Hyperostosis (osteosclerosis in advanced disease) - HP:0002653 Bone pain

Severity: Moderate to severe, major source of morbidity especially in young men Age of onset: Adult Progression: Can be progressive in advanced SM (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, lee2023recentadvancesin pages 3-5, beyens2023mastocytosisandrelated pages 5-8)

Hematological Abnormalities (Frequency: Common in Advanced SM, Rare in ISM): - HP:0001903 Anemia - HP:0001873 Thrombocytopenia - HP:0001876 Pancytopenia - HP:0001880 Eosinophilia

Severity: Severe in advanced SM (C-finding) Frequency: Defining feature of aggressive SM when present as organ dysfunction (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, lee2023recentadvancesin pages 3-5)

Gastrointestinal Manifestations (Frequency: Common): - HP:0002570 Steatorrhea - HP:0004325 Decreased body weight (malabsorption) - HP:0001824 Weight loss

Severity: Variable, severe in advanced SM Frequency: Common in ISM (mediator-related), defining C-finding when malabsorption present in ASM (beyens2023mastocytosisandrelated pages 1-5, lee2023recentadvancesin pages 3-5)

Hepatosplenic Manifestations (Frequency: Common in Advanced SM): - HP:0001392 Abnormality of the liver - HP:0001410 Decreased liver function - HP:0001403 Macrovesicular hepatic steatosis - HP:0001541 Ascites - HP:0001409 Portal hypertension

Severity: Severe when present Frequency: C-finding in advanced SM (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, lee2023recentadvancesin pages 3-5)

Neuropsychiatric Manifestations (Frequency: Less Common but Recognized): - HP:0002315 Headache - HP:0001250 Seizures - HP:0002076 Migraine - HP:0000709 Psychosis (rare) - HP:0000716 Depression

Severity: Variable Frequency: Reported but less systematically studied (cilloni2024detectionofkit pages 1-2)

Quality of Life Impact

Quality of life is significantly impaired across SM subtypes due to chronic symptoms, unpredictable anaphylaxis risk, bone disease with fracture risk, and in advanced disease, organ dysfunction. Mediator-related symptoms including flushing, pruritus, gastrointestinal disturbances, fatigue, and recurrent anaphylaxis substantially reduce daily functioning. Bone involvement causes chronic pain and mobility limitations. Advanced SM is associated with markedly reduced quality of life and life expectancy (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2).

4. Genetic/Molecular Information

Causal Genes

Primary Gene: KIT (HGNC:6342, OMIM:164920) Gene Product: KIT proto-oncogene, receptor tyrosine kinase (CD117) Chromosomal Location: 4q12

Pathogenic Variants

Most Common Mutation: - KIT p.D816V (c.2447A>T): Present in 85-90% or >90% of adult SM cases - Variant type: Missense mutation - Allele frequency: Somatic mutation, not present in germline in typical SM - Variant classification: Pathogenic driver mutation - Functional consequence: Gain of function—constitutive KIT activation independent of SCF ligand - Origin: Somatic (acquired), rarely germline in familial cases (~1.5% of mastocytosis) (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, toledo2023kitd816vmast pages 1-2)

Other KIT Mutations (<5-10% of SM cases): - V560G (exon 11) - D815K - D816Y - D816F - D816H - D820G - insVI815-816 - Variant classification: Pathogenic - Functional consequence: Gain of function - Origin: Somatic (pardanani2023systemicmastocytosisin pages 1-2)

Pediatric CM-Associated KIT Mutations: - Present in approximately 30% of childhood cutaneous mastocytosis - Often involve different codons than D816V - Some may be germline or early postzygotic (pardanani2023systemicmastocytosisin pages 1-2)

Co-occurring Mutations (Associated Hematologic Neoplasm Component, Prognostic Impact)

High-Risk Mutations Associated with Progression and Poor Survival: - ASXL1 (Additional Sex Combs Like 1): Epigenetic regulator - RUNX1 (Runt-related transcription factor 1): Transcription factor - SRSF2 (Serine and arginine rich splicing factor 2): Splicing factor - NRAS (Neuroblastoma RAS viral oncogene homolog): Signaling molecule - Variant type: Various (missense, frameshift, nonsense) - Functional consequence: Loss of function (tumor suppressors/regulators) or gain of function (oncogenes) - Origin: Somatic - Frequency: Variable, enriched in advanced SM (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Other Recurrently Mutated Genes: - TET2 (Ten-eleven translocation 2): Epigenetic regulator - DNMT3A (DNA methyltransferase 3 alpha): DNA methylation - CBL (Casitas B-lineage lymphoma): E3 ubiquitin ligase - EZH2 (Enhancer of zeste homolog 2): Histone methyltransferase - JAK2, KRAS, SF3B1 - Origin: Somatic (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Modifier Genes

Hereditary alpha-tryptasemia (HαT) genotype: - Gene: TPSAB1 (Tryptase alpha/beta 1) - Mechanism: Germline copy number variation—increased copies of alpha-tryptase-encoding TPSAB1 - Effect: Elevates baseline serum tryptase levels (typically >8 ng/mL) - Prevalence in general population: ~5% - Prevalence in SM: Increased 2-3× compared to general population - Impact: May modify symptom severity, particularly anaphylaxis risk, though clinical impact remains under investigation (beyens2023mastocytosisandrelated pages 1-5, li2023reviewandupdates pages 2-4)

Epigenetic Information

Epigenetic dysregulation is implicated through mutations in epigenetic modifier genes including TET2 (demethylation), DNMT3A (DNA methylation), ASXL1 (chromatin remodeling), and EZH2 (histone methylation). These alterations affect gene expression and contribute to disease progression, particularly in advanced SM (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2).

Chromosomal Abnormalities

Complex karyotype is identified as an adverse prognostic factor in advanced SM, associated with significantly worse overall survival (HR 4.2 [1.8-10.0], p=0.016 in allogeneic transplant cohort). Specific recurrent chromosomal translocations are not characteristic of typical SM, but cytogenetic abnormalities may be seen in associated hematologic neoplasms (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2).

5. Environmental Information

Environmental Factors

Given the clonal genetic nature of SM driven by somatic KIT mutations, specific environmental toxins, radiation, or occupational exposures have not been established as causal factors.

Lifestyle Factors

No specific lifestyle factors (smoking, diet, exercise, alcohol) have been established as causal. However, patients are advised to avoid known mast cell triggers including certain medications (NSAIDs, opiates, contrast agents), alcohol, temperature extremes, and physical/emotional stress to prevent mediator release and anaphylaxis (beyens2023mastocytosisandrelated pages 1-5).

Infectious Agents

Not applicable—SM is not caused by infectious agents.

6. Mechanism / Pathophysiology

Molecular Pathways

KIT Signaling Cascade: - KIT receptor tyrosine kinase activation (normally by SCF binding, constitutive in KIT D816V) - Receptor dimerization and autophosphorylation - Activation of downstream pathways: - MAPK/ERK pathway (GO:0000165): Cell proliferation, differentiation - PI3K-AKT-mTOR pathway (GO:0014065): Cell survival, growth, metabolism - JAK-STAT pathway (GO:0007259): Gene transcription, proliferation - Src family kinases: Various signaling functions - Result: Enhanced mast cell proliferation, survival, maturation defects, and activation (pardanani2023systemicmastocytosisin pages 1-2, li2023reviewandupdates pages 2-4, toledo2023kitd816vmast pages 1-2)

FcεRI-Mediated Signaling: - High-affinity IgE receptor on mast cells - Cross-linking by antigen-bound IgE triggers degranulation - Synergistic enhancement with KIT signaling in neoplastic mast cells - Contributes to mediator release and clinical symptoms (li2023reviewandupdates pages 2-4)

Cellular Processes

Abnormal Mast Cell Proliferation and Survival (GO:0008283, GO:0043066): - Constitutive KIT activation drives unchecked proliferation - Resistance to apoptosis through PI3K-AKT pathway - Accumulation in tissues (bone marrow, skin, GI tract, liver, spleen, bone) (pardanani2023systemicmastocytosisin pages 1-2, li2023reviewandupdates pages 2-4, toledo2023kitd816vmast pages 1-2)

Impaired Mast Cell Differentiation and Maturation: - Abnormal mast cell morphology: spindle-shaped, hypogranular, atypical nuclei - Aberrant immunophenotype: CD25+, CD2+, and/or CD30+ expression (normally absent on mature mast cells) - Retained high CD117 (KIT) expression (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, li2023reviewandupdates pages 2-4, lee2023recentadvancesin pages 3-5)

Mast Cell Activation and Degranulation (GO:0043303, GO:0043304): - Enhanced mediator release: histamine, tryptase, prostaglandin D2 (PGD2), leukotrienes (LTC4, LTD4, LTE4), platelet-activating factor - Cytokine release: TNF-α, TNF-β, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF - Chemokine release: IL-8, MCP-1, MIP-1α - Clinical manifestations: flushing, pruritus, urticaria, GI symptoms, anaphylaxis, cardiovascular symptoms (li2023reviewandupdates pages 2-4)

Cell Type Involved: - Primary: Neoplastic mast cells (CL:0000097) - Secondary: Osteoclasts, osteoblasts (bone disease), various inflammatory cells recruited by mast cell mediators

Protein Dysfunction

KIT Receptor: - Normal function: Ligand (SCF)-dependent activation, tightly regulated signaling - Mutant KIT D816V: Constitutive activation independent of ligand - Structural impact: Mutation in activation loop of tyrosine kinase domain stabilizes active conformation - Resistance to some tyrosine kinase inhibitors (e.g., imatinib) (pardanani2023systemicmastocytosisin pages 1-2, toledo2023kitd816vmast pages 1-2)

Metabolic Changes

Specific metabolic pathway alterations have not been comprehensively characterized, though mast cell mediators affect various metabolic processes including vascular permeability, smooth muscle contraction, and inflammatory responses.

Immune System Involvement

Mast Cell Function in Immunity: - Normally: Sentinel cells in innate and adaptive immunity, allergic reactions - In SM: Dysregulated activation leads to chronic inflammation, exaggerated allergic responses, increased anaphylaxis risk - Mechanism: Both IgE-dependent and IgE-independent mast cell activation - Immune mediators: Cytokines, chemokines driving inflammatory milieu (li2023reviewandupdates pages 2-4)

Tissue Damage Mechanisms

Bone Involvement: - Dual effects: Osteoporosis (most common in ISM) and osteosclerosis (advanced SM) - Pathogenesis: Mast cell-derived mediators (histamine, tryptase, TNF-α, IL-6, RANKL) promote osteoclastogenesis, suppress osteoblast function - Outcome: Pathological fractures, bone pain, skeletal deformity (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2)

Organ Infiltration (Advanced SM): - Mast cell accumulation in bone marrow, liver, spleen, GI tract - Mechanisms: Direct infiltration causing organ dysfunction, fibrosis - C-findings: Cytopenias (marrow), hepatic dysfunction/portal hypertension/ascites (liver), hypersplenism (spleen), malabsorption (GI) (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, lee2023recentadvancesin pages 3-5)

Biochemical Abnormalities

• Elevated serum tryptase (>20 ng/mL): Reflects mast cell burden
• Elevated urinary histamine metabolites (N-methylhistamine, 1-methyl-4-imidazoleacetic acid)
• Increased prostaglandin D2 and leukotrienes
• These serve as biomarkers of mast cell activation and burden (li2023reviewandupdates pages 2-4, lee2023recentadvancesin pages 3-5)

Molecular Profiling

Transcriptomics: - KIT D816V mast cells show upregulated expression of genes involved in innate immunity, inflammatory responses, and proliferation - iPSC-derived KIT D816V mast cells recapitulate SM transcriptional signatures (toledo2023kitd816vmast pages 1-2)

Proteomics: - Increased tryptase (beta-tryptase primarily), chymase, carboxypeptidase A3 - Aberrant surface markers: CD25, CD2, CD30 (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, li2023reviewandupdates pages 2-4, lee2023recentadvancesin pages 3-5)

7. Anatomical Structures Affected

Organ Level

Primary Organs Directly Affected: - Bone marrow (UBERON:0002371): Universal involvement in SM; dense mast cell infiltrates, spindle-shaped morphology - Skin (UBERON:0002097): Maculopapular cutaneous involvement in ISM, less common in advanced SM - Bone (UBERON:0001474): Osteoporosis, osteosclerosis, pathological fractures - Gastrointestinal tract (UBERON:0001555): Mast cell infiltration, malabsorption in advanced disease - Liver (UBERON:0002107): Hepatomegaly, portal fibrosis, dysfunction in advanced SM - Spleen (UBERON:0002106): Splenomegaly, hypersplenism in advanced SM (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, li2023reviewandupdates pages 2-4, lee2023recentadvancesin pages 3-5, beyens2023mastocytosisandrelated pages 5-8)

Secondary Organ Involvement: - Lymph nodes (UBERON:0000029): Lymphadenopathy in advanced disease - Cardiovascular system (UBERON:0004535): Hypotension, tachycardia from mediator release, rare cardiac involvement

Body Systems Involved: - Hematopoietic system (UBERON:0002390) - Integumentary system (UBERON:0002416) - Skeletal system (UBERON:0001434) - Digestive system (UBERON:0001007) - Immune system (UBERON:0002405)

Tissue and Cell Level

Tissue Types Affected: - Hematopoietic/lymphoid tissue (UBERON:0002193) - Connective tissue (UBERON:0002384): Bone matrix, skin dermis - Epithelial tissue (UBERON:0000483): GI mucosa

Specific Cell Populations: - Neoplastic mast cells (CL:0000097): Abnormal morphology, immunophenotype, and function - Osteoclasts (CL:0000092) and osteoblasts (CL:0000062): Dysregulated in bone disease - Hepatocytes (CL:0000182): Affected in hepatic involvement - Hematopoietic stem cells (CL:0000037): May harbor KIT D816V in multilineage involvement

Subcellular Level

Cellular Compartments Involved (GO Cellular Component): - Plasma membrane (GO:0005886): KIT receptor localization - Cytoplasmic granules (GO:0031410): Mast cell secretory granules containing mediators - Nucleus (GO:0005634): Altered gene transcription - Mitochondria (GO:0005739): Involved in cellular metabolism and survival signaling

Localization

Anatomical Sites: - Bone marrow: Paratrabecular and perisinusoidal distribution of mast cells - Skin: Dermis, perivascular areas - GI tract: Lamina propria - Liver: Portal areas - Distribution: Bilateral, systemic (li2023reviewandupdates pages 2-4)

8. Temporal Development

Onset

Typical Age of Onset: - Adults: 20-50 years for systemic mastocytosis - Children: 75-80% of cutaneous mastocytosis cases occur within first 2 years of life - Pediatric CM often regresses spontaneously at puberty; adult-onset SM typically persists (beyens2023mastocytosisandrelated pages 1-5, cilloni2024detectionofkit pages 1-2)

Onset Pattern: - Variable: Can be insidious (gradual symptom onset) or acute (sudden anaphylaxis) - Many patients have long-standing symptoms before diagnosis (beyens2023mastocytosisandrelated pages 1-5)

Progression

Disease Stages: - Non-advanced SM: BMM, ISM, SSM—low mast cell burden, preserved organ function - Advanced SM: ASM, SM-AHN, MCL—high disease burden, organ dysfunction (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Progression Rate: - ISM: Typically slow or stable, near-normal life expectancy - SSM: Higher risk of progression to advanced SM (≥2 B-findings) - ASM/SM-AHN/MCL: Rapid, aggressive course with poor prognosis (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Disease Course Pattern: - ISM: Chronic, stable or slowly progressive - SSM: Chronic with risk of transformation - ASM: Progressive - MCL: Rapidly progressive - Disease duration: Typically lifelong once established (except pediatric CM) (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5)

Patterns

Remission: - Spontaneous remission: Common in pediatric cutaneous mastocytosis (~50-80% by adolescence) - Treatment-induced remission: Possible with tyrosine kinase inhibitors (midostaurin, avapritinib) but typically not curative - Allogeneic stem cell transplant: Only potentially curative therapy (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Critical Periods: - Diagnosis: Early recognition critical for anaphylaxis prevention - Transformation: SSM to ASM transformation represents critical disease acceleration - Treatment initiation: Advanced SM requires prompt cytoreductive therapy (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

9. Inheritance and Population

Epidemiology

Prevalence: Approximately 1 case per 10,000 persons in adults (Orphanet data) (cilloni2024detectionofkit pages 1-2)

Incidence: Specific annual incidence data not well established due to disease rarity and diagnostic challenges.

For Genetic Etiology

Inheritance Pattern: - Typical SM: Sporadic, acquired somatic KIT mutations (non-inherited) - Familial mastocytosis: Extremely rare (~1.5% of cases), may involve germline KIT mutations, pattern unclear but likely autosomal dominant with variable penetrance (beyens2023mastocytosisandrelated pages 1-5, cilloni2024detectionofkit pages 1-2)

Penetrance: - Somatic KIT D816V: Not applicable (acquired) - Germline KIT mutations (familial): Likely incomplete penetrance given rarity

Expressivity: - Highly variable clinical phenotypes from indolent to aggressive disease - Influenced by co-occurring mutations, multilineage involvement, and HαT status (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Genetic Anticipation: Not described

Germline Mosaicism: May occur but not well characterized

Founder Effects: Not described for KIT D816V as it arises somatically

Consanguinity Role: Not relevant for sporadic somatic mutations

Carrier Frequency: Not applicable (somatic disease)

Population Demographics

Affected Populations: - No specific ethnic predilection documented - Affects diverse populations globally (cilloni2024detectionofkit pages 1-2)

Geographic Distribution: - Worldwide distribution - No known endemic areas (cilloni2024detectionofkit pages 1-2)

Sex Ratio: - Approximately 1:1 male:female (cilloni2024detectionofkit pages 1-2)

Age Distribution: - Adults: Peak onset 20-50 years - Children: Peak onset <2 years for cutaneous forms (beyens2023mastocytosisandrelated pages 1-5, cilloni2024detectionofkit pages 1-2)

10. Diagnostics

Clinical Tests

Laboratory Tests: - Serum tryptase (LOINC:2338-5): Baseline serum tryptase >20 ng/mL is a minor diagnostic criterion; normal range 1-15 ng/mL; must be adjusted for hereditary alpha-tryptasemia. Tryptase >200 ng/mL is a B-finding (high disease burden) (pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, li2023reviewandupdates pages 2-4, lee2023recentadvancesin pages 3-5) - Complete blood count: Assess for cytopenias, eosinophilia - Liver function tests: Assess hepatic involvement - Serum alkaline phosphatase: May be elevated (B-finding) - Serum albumin: May be decreased (malabsorption, C-finding) - Urinary histamine metabolites: N-methylhistamine, 1-methyl-4-imidazoleacetic acid (mast cell activation markers)

Biomarkers: - Tryptase (serum, beta-tryptase isoforms): Most specific mast cell biomarker, reflects burden and activation - CD25, CD2, CD30: Aberrant surface markers on neoplastic mast cells (minor diagnostic criteria) - Prostaglandin D2 and metabolites: Mast cell activation - IgE levels: Assess atopic background (pardanani2023systemicmastocytosisin pages 1-2, li2023reviewandupdates pages 2-4, lee2023recentadvancesin pages 3-5)

Imaging Studies: - Bone densitometry (DEXA scan): Evaluate osteoporosis/osteosclerosis - CT scan: Assess organomegaly, lymphadenopathy, skeletal lesions - MRI: Detailed bone marrow and organ assessment - Abdominal ultrasound: Hepatosplenomegaly screening (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, beyens2023mastocytosisandrelated pages 5-8)

Biopsy Findings: - Bone marrow biopsy (major diagnostic criterion): Multifocal dense aggregates of ≥15 mast cells (tryptase+, CD117+) - Histopathology: Spindle-shaped or atypical mast cell morphology - Immunohistochemistry: CD117+, tryptase+, CD25+, CD2+, and/or CD30+ (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, lee2023recentadvancesin pages 3-5)

Flow Cytometry: - Bone marrow or peripheral blood - Aberrant mast cell immunophenotype: CD117+, CD25+, CD2+, CD30+ - Helps confirm minor diagnostic criteria (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, lee2023recentadvancesin pages 3-5)

Genetic Testing

Recommended Approach: - High-sensitivity KIT mutation testing from bone marrow or peripheral blood - Test for KIT D816V first (most common) - If negative, test for other KIT mutations (D815K, D816Y, V560G, etc.)

Molecular Methods: - Allele-specific PCR (AS-PCR): High sensitivity for KIT D816V (detection limit ~0.1-1% variant allele frequency) - Digital droplet PCR (ddPCR): Very high sensitivity (<0.01% VAF) - Next-generation sequencing (NGS): Panel testing for KIT and co-occurring mutations (ASXL1, RUNX1, SRSF2, NRAS, TET2, etc.); standard NGS may miss low-VAF KIT mutations - Bone marrow preferred over blood for highest sensitivity (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, toledo2023kitd816vmast pages 1-2)

Tryptase Genotyping: - TPSAB1 copy number variation testing for hereditary alpha-tryptasemia - Indicated when interpreting elevated baseline serum tryptase, especially for WHO/ICC minor criterion assessment - Method: Droplet digital PCR (beyens2023mastocytosisandrelated pages 1-5, li2023reviewandupdates pages 2-4)

Gene Panels: - Myeloid mutation panels including KIT, ASXL1, RUNX1, SRSF2, NRAS, TET2, DNMT3A, CBL, EZH2, JAK2 - Important for risk stratification in advanced SM (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Clinical Criteria

WHO 2022 / ICC 2022 Diagnostic Criteria for SM:

Major Criterion: - Multifocal dense aggregates of mast cells (≥15 mast cells) in bone marrow and/or extracutaneous organs

Minor Criteria (need 1 major + 1 minor, OR 3 minor criteria): 1. ≥25% atypical/spindle-shaped mast cells in marrow or tissue 2. Activating KIT mutation (D816V or other) in marrow, blood, or tissue 3. Aberrant CD25 and/or CD2 and/or CD30 expression on mast cells 4. Persistent baseline serum tryptase >20 ng/mL (adjusted for HαT, not counted in SM-AMN) (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, lee2023recentadvancesin pages 3-5)

Differential Diagnosis: - Mast cell activation syndrome (MCAS): Symptoms of mast cell activation without SM criteria - Monoclonal mast cell activation syndrome (MMAS): Clonal mast cells (KIT+) but only 2 SM minor criteria - Cutaneous mastocytosis: Skin-limited, no systemic involvement - Secondary mast cell hyperplasia: Reactive, non-clonal - Hypereosinophilic syndromes - Other myeloid neoplasms (li2023reviewandupdates pages 1-2, beyens2023mastocytosisandrelated pages 1-5, li2023reviewandupdates pages 2-4)

Screening

Indications for Bone Marrow Evaluation: - Adult-onset cutaneous lesions (typical urticaria pigmentosa/maculopapular lesions) - Recurrent, unexplained, or severe anaphylaxis (especially without mucocutaneous symptoms) - Hymenoptera venom allergy with severe anaphylaxis - Persistent elevated baseline serum tryptase >20 ng/mL (adjusted for HαT) - Unexplained osteoporosis or fragility fractures, especially lumbar spine - REMA score or NICAS score suggesting high SM risk (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, beyens2023mastocytosisandrelated pages 5-8)

11. Outcome/Prognosis

Survival and Mortality

Non-Advanced SM (ISM, BMM): - Life expectancy: Near normal, often compatible with normal lifespan - Mortality primarily from anaphylaxis risk rather than disease progression (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Smoldering SM (SSM): - Intermediate prognosis - Higher risk of progression to advanced SM compared to ISM (li2023reviewandupdates pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Advanced SM (ASM, SM-AHN, MCL): - Median overall survival (historical): - ASM/SM-AHN: Approximately 1.9-9.0 years (variable by subtype and treatment) - SM-AML: Median 3.3 years - MCL: Median 0.9 years (worst prognosis) - Disease-specific mortality high in advanced SM - Recent tyrosine kinase inhibitor therapies (avapritinib) have shown improved survival compared to best available therapy (HR 0.48 [0.29, 0.79], p=0.004) (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Prognostic Factors

Adverse Prognostic Markers: - Advanced SM subtype (ASM, SM-AHN, MCL) - Absence of KIT D816V (10/61, 16% of cohort, HR 2.9 [1.2-6.5], p<0.001) - Complex karyotype (HR 4.2 [1.8-10.0], p=0.016) - Co-occurring mutations: ASXL1, RUNX1, SRSF2, NRAS - Multilineage KIT involvement - Mast cell leukemia diagnosis - Eosinophilia ≥1.5×10^9/L - Lack of treatment response - <3 cycles of cladribine treatment (if applicable) (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Favorable Prognostic Markers: - ISM or BMM subtype - Presence of KIT D816V - Absence of high-risk co-mutations - Response to cytoreductive therapy (ASM/SM-AHN/MCL) - Treatment response before allogeneic transplant (if applicable) (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Prognostic Scoring Systems: - MARS (Mutation-Adjusted Risk Score) - IPSM (International Prognostic Scoring System for Mastocytosis) - MAPS (Mutation-Augmented Prognostic Score) - GPSM (Global Prognostic Score for Mastocytosis) These incorporate genetic mutations, clinical parameters, and disease burden markers (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Quality of Life

Quality of life is significantly impaired in SM due to chronic symptoms, anaphylaxis risk, bone disease, and in advanced disease, organ dysfunction and treatment toxicity. Tyrosine kinase inhibitors (avapritinib) have demonstrated improvements in quality of life measures through reduction of mast cell burden and symptom control (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2).

12. Treatment

Pharmacotherapy

Symptomatic/Mediator-Targeted Therapy (All SM Subtypes):

Antihistamines: - H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine): For pruritus, urticaria, flushing - H2-antihistamines (e.g., ranitidine, famotidine): For GI symptoms, acid suppression - MAXO:0000058 (antihistamine therapy) (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Mast Cell Stabilizers: - Cromolyn sodium: Oral for GI symptoms - MAXO:0000624 (mast cell stabilizer therapy) (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Leukotriene Antagonists: - Montelukast: For respiratory symptoms (beyens2023mastocytosisandrelated pages 1-5)

Epinephrine: - Auto-injector: Essential for all SM patients (anaphylaxis prevention) - MAXO:0000724 (emergency medication) (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Aspirin (in selected patients): - Low-dose for flushing (after tolerance testing) (beyens2023mastocytosisandrelated pages 1-5)

Proton Pump Inhibitors: - For GI symptoms, peptic ulcer disease (beyens2023mastocytosisandrelated pages 1-5)

Bone-Directed Therapy (ISM with Osteoporosis):

Bisphosphonates: - Alendronate, zoledronic acid: Anti-resorptive - MAXO:0000127 (bisphosphonate therapy) (li2023reviewandupdates pages 1-2, beyens2023mastocytosisandrelated pages 1-5)

Denosumab: - RANKL inhibitor: Anti-resorptive (li2023reviewandupdates pages 1-2)

Anabolic Agents: - Teriparatide, abaloparatide: Bone formation promotion (li2023reviewandupdates pages 1-2)

Cytoreductive Therapy (Advanced SM):

Tyrosine Kinase Inhibitors (TKIs):

• Midostaurin: Multi-kinase inhibitor targeting KIT D816V, PKC, FLT3
• FDA approved for advanced SM (ASM, SM-AHN, MCL)
• Dosing: 100 mg PO BID
• Response rate: 40-60% in advanced SM

• MAXO:0000605 (tyrosine kinase inhibitor therapy) (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

• Avapritinib: Selective KIT D816V inhibitor

• FDA approved for advanced SM
• Also approved for indolent SM based on PIONEER trial (2023)
• Dosing: 200 mg PO daily (advanced SM), 25 mg PO daily (ISM)
• Superior efficacy vs best available therapy in advanced SM: HR for overall survival 0.48 (95% CI 0.29-0.79, p=0.004)
• Mean tryptase reduction 60.3% greater than BAT (p<0.001)
• Duration of treatment significantly longer than BAT (HR 0.36, p<0.001)
• Can reverse both osteoporosis and osteosclerosis
• MAXO:0000605 (tyrosine kinase inhibitor therapy) (li2023reviewandupdates pages 1-2, lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Purine Analogues: - Cladribine (2-CdA): Cytotoxic, mast cell debulking - Overall response rate: 41% (1st-line), 35% (2nd-line) - Median OS: 1.9 years (1st-line), 1.2 years (2nd-line) - Effective in some refractory cases - MAXO:0001487 (cladribine therapy) (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Interferon-alpha: - Historical role, diminishing use in TKI era - May have role in resource-limited settings - MAXO:0000091 (interferon therapy) (pardanani2023systemicmastocytosisin pages 1-2)

Imatinib: - Only effective for rare imatinib-sensitive KIT mutations (e.g., F522C, K509I in exon 9) - Ineffective against KIT D816V due to steric hindrance (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Advanced Therapeutics

Allogeneic Hematopoietic Cell Transplantation: - Only potentially curative therapy for advanced SM - Indications: ASM, SM-AML, MCL in selected patients - Median overall survival by subtype (German DRST/GREM registries, 1999-2021): - ASM/SM-AHN: 9.0 years - SM-AML: 3.3 years - MCL ± AHN: 0.9 years - Favorable prognostic factors: Treatment response of SM and/or AHN prior to transplant - Adverse factors: Absence of KIT D816V, complex karyotype - MAXO:0000747 (allogeneic hematopoietic stem cell transplantation) (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Emerging Therapies (Investigational, Clinical Trials): - Bezuclastinib: Selective KIT inhibitor - Elenestinib: Novel KIT inhibitor - Combination strategies: TKI + chemotherapy for SM-AHN - Mast cell silencing approaches: Siglec-8 agonists (lirentelimab), Siglec-6 agonists, CD200R agonists (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Treatment Outcomes

Avapritinib (PATHFINDER/EXPLORER trials, advanced SM): - Overall response rate: ~75% - Complete remission + partial remission rates: Significant - Median duration of response: >2 years in responders - Adverse events: Mostly manageable; cognitive effects, periorbital edema, GI toxicity (lee2023recentadvancesin pages 1-2, pardanani2023systemicmastocytosisin pages 1-2)

Midostaurin (advanced SM): - Overall response rate: 40-60% - Side effects: GI toxicity, fatigue, cytopenias (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Treatment Strategy

Treatment Algorithms:

ISM/BMM: 1. Symptomatic therapy (antihistamines, mast cell stabilizers, epinephrine auto-injector) 2. Osteoporosis prevention/treatment 3. Avoidance of mast cell triggers 4. Consider avapritinib for refractory symptoms (based on PIONEER trial, 2023) (li2023reviewandupdates pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

SSM: 1. Similar to ISM with closer monitoring 2. Consider early cytoreductive therapy if progression (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

ASM: 1. Tyrosine kinase inhibitor (avapritinib or midostaurin) 2. Supportive care 3. Consider allogeneic transplant in selected patients (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

SM-AHN: 1. Treat AHN component (chemotherapy for AML, hypomethylating agents for MDS, etc.) 2. Add KIT inhibitor (midostaurin or avapritinib) 3. Consider allogeneic transplant (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

MCL: 1. Intensive therapy: TKI (avapritinib preferred) 2. Consider allogeneic transplant early if feasible 3. Clinical trial enrollment (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Personalized Medicine Approaches: - KIT mutation testing to guide TKI selection - Tryptase genotyping (HαT) to interpret biomarkers and adjust thresholds - Mutation profiling (ASXL1, RUNX1, SRSF2, NRAS) for risk stratification - Treatment response assessment by tryptase reduction, molecular response (KIT D816V VAF) (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, cilloni2024detectionofkit pages 1-2, li2023reviewandupdates pages 2-4)

13. Prevention

Prevention Levels

Primary Prevention: Not applicable given clonal/somatic mutation etiology; no interventions prevent initial SM development.

Secondary Prevention (Early Detection): - Screening high-risk individuals: Those with recurrent anaphylaxis, unexplained osteoporosis, persistent elevated tryptase - Bone marrow biopsy when suspicion high (clinical criteria, biomarkers) - Early diagnosis enables anaphylaxis preparedness and symptom management (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, beyens2023mastocytosisandrelated pages 5-8)

Tertiary Prevention (Preventing Complications): - Anaphylaxis prevention: Epinephrine auto-injector, avoidance of triggers (NSAIDs, opiates, contrast agents, alcohol, temperature extremes, physical/emotional stress), venom immunotherapy (if hymenoptera allergy), premedication before procedures - Osteoporosis prevention: Bone-directed therapy (bisphosphonates, denosumab), vitamin D/calcium supplementation, weight-bearing exercise - Disease progression monitoring: Regular tryptase monitoring, bone marrow reassessment if clinical change, mutation monitoring - Infection prevention: During cytoreductive therapy (prophylactic antibiotics/antivirals if indicated) (li2023reviewandupdates pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Screening and Early Detection

Screening Programs: - No population-based screening - Targeted screening of symptomatic individuals and first-degree relatives (if familial mastocytosis) (beyens2023mastocytosisandrelated pages 1-5)

Genetic Screening: - Not routinely recommended given sporadic nature - Consider in rare familial cases (germline KIT mutation testing) - Tryptase genotyping (HαT) increasingly used to interpret tryptase elevations (beyens2023mastocytosisandrelated pages 1-5, li2023reviewandupdates pages 2-4)

Risk Stratification: - REMA score and NICAS score for anaphylaxis patients - Prognostic scoring (MARS, IPSM, MAPS, GPSM) for advanced SM (lee2023recentadvancesin pages 1-2, beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2, beyens2023mastocytosisandrelated pages 5-8)

Counseling

Genetic Counseling: - Indicated for familial mastocytosis cases - Discussion of recurrence risk (very low for typical sporadic SM) - Family planning guidance if germline KIT mutation identified (beyens2023mastocytosisandrelated pages 1-5)

Public Health

Public health interventions not applicable given rarity and non-communicable nature.

Prophylaxis

Medications: - Chronic antihistamines (H1 and H2 blockers) - Mast cell stabilizers (cromolyn) - Epinephrine auto-injector (all patients) (beyens2023mastocytosisandrelated pages 1-5, pardanani2023systemicmastocytosisin pages 1-2)

Procedures: - Venom immunotherapy (VIT) for hymenoptera venom allergy: Reduces anaphylaxis risk but may need lifelong continuation in SM (beyens2023mastocytosisandrelated pages 1-5, beyens2023mastocytosisandrelated pages 5-8)

14. Other Species / Natural Disease

Taxonomy and Natural Disease

Species Affected: - Canine (Canis lupus familiaris, NCBI:txid9615): Canine mast cell tumors (MCTs) are common, often involving KIT mutations - Feline (Felis catus, NCBI:txid9685): Feline mastocytosis described - Murine (Mus musculus, NCBI:txid10090): Not naturally occurring but extensively modeled (Brief mention in general literature; detailed veterinary data not extensively covered in retrieved sources)

Gene Orthology: - KIT gene is highly conserved across mammals - Human KIT (HGNC:6342) has orthologs in mouse (MGI:96677), dog, cat, other species

Natural Disease in Animals: - Canine MCTs are common neoplasms; some harbor KIT mutations (exon 11 more common than D816V in dogs) - Veterinary relevance: MCTs are important clinical problems in dogs; some response to toceranib (KIT inhibitor) (Not primary focus of retrieved human-focused sources)

Comparative Biology

Comparative pathology suggests conserved KIT signaling mechanisms across species; mast cell biology and KIT function are evolutionarily conserved.

15. Model Organisms

Model Types

Mammalian Models:

Mouse Models (Mus musculus, NCBI:txid10090): - Transgenic/knock-in models: Expression of KIT D816V or other activating KIT mutations in hematopoietic cells - Transplantation models: KIT-mutant bone marrow transplant into recipient mice - Phenotype recapitulation: Variable; some models show mast cell expansion, organomegaly, but may not fully recapitulate human SM features - Limitations: Murine mast cell biology differs from human; incomplete phenotype reproduction (toledo2023kitd816vmast pages 1-2)

Induced Pluripotent Stem Cell (iPSC) Models: - Patient-derived iPSC lines carrying KIT D816V mutation - Differentiation to mast cells in vitro - Phenotype recapitulation: KIT D816V iPSC-derived mast cells show: - Increased mast cell numbers - Abnormal maturation kinetics - Activated phenotype - CD25 and CD30 expression - Transcriptional signature with upregulated innate/inflammatory response genes matching primary SM mast cells - Applications: Disease modeling, drug screening, mechanistic studies - Advantages: Unlimited cell source, patient-specific genetic background, close-to-human model (toledo2023kitd816vmast pages 1-2)

Potential Invertebrate/Other Models: - Zebrafish (Danio rerio, NCBI:txid7955): Emerging model for inflammation and mast cell research, though not specifically for SM modeling - Utility: Rapid development, genetic tractability, in vivo imaging (General zebrafish inflammation studies mentioned; not SM-specific in retrieved sources)

Genetic Models

Available Types: - Knock-in: KIT D816V introduced into mouse hematopoietic cells - Transgenic: Conditional expression of mutant KIT - Xenograft: Human SM cells or iPSC-derived mast cells transplanted into immunodeficient mice (toledo2023kitd816vmast pages 1-2)

Model Limitations

• Mouse models do not fully recapitulate all aspects of human SM (bone disease, mediator-related symptoms, clinical heterogeneity)
• iPSC models are in vitro, lack tissue microenvironment and systemic interactions
• Zebrafish lack true mast cells homologous to mammalian mast cells

Applications

• Mechanistic studies: KIT signaling pathways, co-mutation effects, multilineage involvement
• Drug screening: Testing TKIs and novel therapeutics
• Biomarker discovery: Transcriptomics, proteomics in controlled models (toledo2023kitd816vmast pages 1-2)

Resources

• Mouse Genome Informatics (MGI): Mouse model data
• International Mouse Strain Resource (IMSR): Repository of mouse models
• iPSC repositories: Patient-derived lines available through research collaborations

Summary

Systemic mastocytosis is a rare clonal hematopoietic neoplasm characterized by abnormal accumulation of neoplastic mast cells in bone marrow and extracutaneous organs. The disease is predominantly driven by the KIT D816V mutation (>90% of cases), which causes constitutive KIT receptor activation, leading to mast cell proliferation, survival, and activation. SM is classified into non-advanced subtypes (BMM, ISM, SSM) and advanced subtypes (ASM, SM-AHN, MCL) based on disease burden and organ dysfunction (WHO/ICC 2022 criteria). Clinical manifestations range from mediator-related symptoms (anaphylaxis, flushing, GI symptoms) to organ infiltration and dysfunction in advanced disease. Diagnosis requires integration of bone marrow morphology (major criterion: dense mast cell aggregates), immunophenotyping (CD25, CD2, CD30 expression), molecular testing (KIT mutations), and clinical findings. Serum tryptase serves as a key biomarker. Prognosis varies from near-normal life expectancy in ISM to poor survival in advanced SM. Treatment includes symptomatic management for all patients and cytoreductive therapy with tyrosine kinase inhibitors (midostaurin, avapritinib—FDA approved 2017 and 2021 respectively) for advanced disease. Avapritinib has demonstrated superior efficacy compared to best available therapy and is now approved for both advanced and indolent SM. Allogeneic stem cell transplantation remains the only potentially curative option. Research models include KIT-mutant mouse models and patient-derived iPSC-differentiated mast cells. Recent advances (2022-2024) include refined WHO/ICC diagnostic criteria incorporating CD30, improved KIT mutation detection methods, tryptase genotyping for HαT, and expanding indications for selective KIT inhibitors.

References

1. (li2023reviewandupdates pages 1-2): Julie Y. Li, Christopher B. Ryder, Hailing Zhang, Samuel G. Cockey, Elizabeth Hyjek, Lynn C. Moscinski, Elizabeth Sagatys, and Jinming Song. Review and updates on systemic mastocytosis and related entities. Cancers, 15:5626, Nov 2023. URL: https://doi.org/10.3390/cancers15235626, doi:10.3390/cancers15235626. This article has 39 citations.

2. (lee2023recentadvancesin pages 1-2): Hyun Jung Lee. Recent advances in diagnosis and therapy in systemic mastocytosis. Blood Research, 58:S96-S108, Apr 2023. URL: https://doi.org/10.5045/br.2023.2023024, doi:10.5045/br.2023.2023024. This article has 20 citations.

3. (pardanani2023systemicmastocytosisin pages 1-2): Animesh Pardanani. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. American Journal of Hematology, 98:1097-1116, May 2023. URL: https://doi.org/10.1002/ajh.26962, doi:10.1002/ajh.26962. This article has 137 citations and is from a domain leading peer-reviewed journal.

4. (cilloni2024detectionofkit pages 1-2): Daniela Cilloni, Beatrice Maffeo, Arianna Savi, Alice Costanza Danzero, Valentina Bonuomo, and Carmen Fava. Detection of kit mutations in systemic mastocytosis: how, when, and why. International Journal of Molecular Sciences, 25:10885, Oct 2024. URL: https://doi.org/10.3390/ijms252010885, doi:10.3390/ijms252010885. This article has 18 citations.

5. (toledo2023kitd816vmast pages 1-2): Marcelo A. S. de Toledo, Xuhuang Fu, Tiago Maié, Eva M. Buhl, Katrin Götz, Susanne Schmitz, Anne Kaiser, Peter Boor, Till Braunschweig, Nicolas Chatain, Ivan G. Costa, Tim H. Brümmendorf, Steffen Koschmieder, and Martin Zenke. Kit d816v mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile. International Journal of Molecular Sciences, 24:5275, Mar 2023. URL: https://doi.org/10.3390/ijms24065275, doi:10.3390/ijms24065275. This article has 10 citations.

6. (li2023reviewandupdates pages 2-4): Julie Y. Li, Christopher B. Ryder, Hailing Zhang, Samuel G. Cockey, Elizabeth Hyjek, Lynn C. Moscinski, Elizabeth Sagatys, and Jinming Song. Review and updates on systemic mastocytosis and related entities. Cancers, 15:5626, Nov 2023. URL: https://doi.org/10.3390/cancers15235626, doi:10.3390/cancers15235626. This article has 39 citations.

7. (beyens2023mastocytosisandrelated pages 1-5): Michiel Beyens, Jessy Elst, Marie-Line van der Poorten, Athina Van Gasse, Alessandro Toscano, Anke Verlinden, Katrien Vermeulen, Marie-Berthe Maes, J. N. G. Hanneke Oude Elberink, Didier Ebo, and Vito Sabato. Mastocytosis and related entities: a practical roadmap. Acta Clinica Belgica, 78:325-335, Oct 2023. URL: https://doi.org/10.1080/17843286.2022.2137631, doi:10.1080/17843286.2022.2137631. This article has 11 citations and is from a peer-reviewed journal.

8. (lee2023recentadvancesin pages 3-5): Hyun Jung Lee. Recent advances in diagnosis and therapy in systemic mastocytosis. Blood Research, 58:S96-S108, Apr 2023. URL: https://doi.org/10.5045/br.2023.2023024, doi:10.5045/br.2023.2023024. This article has 20 citations.

9. (beyens2023mastocytosisandrelated pages 5-8): Michiel Beyens, Jessy Elst, Marie-Line van der Poorten, Athina Van Gasse, Alessandro Toscano, Anke Verlinden, Katrien Vermeulen, Marie-Berthe Maes, J. N. G. Hanneke Oude Elberink, Didier Ebo, and Vito Sabato. Mastocytosis and related entities: a practical roadmap. Acta Clinica Belgica, 78:325-335, Oct 2023. URL: https://doi.org/10.1080/17843286.2022.2137631, doi:10.1080/17843286.2022.2137631. This article has 11 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00